Tyrphostin AG1478 Inhibits Encephalomyocarditis Virus and Hepatitis C Virus by Targeting Phosphatidylinositol 4-Kinase IIIα | Zendy

Cristina M. Dorobantu | Zendy; Christian Harak | Zendy; Rahel Klein | Zendy; Lonneke van der Linden | Zendy; Jeroen R. P. M. Strating | Zendy; Hilde M. van der Schaar | Zendy; Volker Lohmann | Zendy; Frank J. M. van Kuppeveld | Zendy

Open Access

Tyrphostin AG1478 Inhibits Encephalomyocarditis Virus and Hepatitis C Virus by Targeting Phosphatidylinositol 4-Kinase IIIα

Author(s) -

Cristina M. Dorobantu,

Christian Harak,

Rahel Klein,

Lonneke van der Linden,

Jeroen R. P. M. Strating,

Hilde M. van der Schaar,

Volker Lohmann,

Frank J. M. van Kuppeveld

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01331-16

Subject(s) - virology , hepatitis c virus , virus , epidermal growth factor receptor , biology , viral replication , kinase , phosphatidylinositol , in vitro , cancer research , receptor , microbiology and biotechnology , biochemistry

Encephalomyocarditis virus (EMCV), like hepatitis C virus (HCV), requires phosphatidylinositol 4-kinase IIIα (PI4KA) for genome replication. Here, we demonstrate that tyrphostin AG1478, a known epidermal growth factor receptor (EGFR) inhibitor, also inhibits PI4KA activity, both in vitro and in cells. AG1478 impaired replication of EMCV and HCV but not that of an EMCV mutant previously shown to escape PI4KA inhibition. This work uncovers novel cellular and antiviral properties of AG1478, a compound previously regarded only as a cancer chemotherapy agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research